神经分泌生物科学（NBIX）周二盘前股价大涨10.28%，引起投资者广泛关注。这一显著涨幅主要受到华尔街分析师积极评价的推动。
加拿大皇家银行（RBC）资本市场分析师将神经分泌生物科学的目标价从137美元上调至145美元，显示出对公司前景的看好。此外，华尔街分析师对该公司股票的平均评级为"买入"，12个月目标价中位数为160美元，进一步凸显了市场对公司长期发展的信心。
值得注意的是，尽管神经分泌生物科学最新公布的季度每股收益低于预期，但公司营收表现亮眼。截至3月31日的季度营收同比增长11.1%，达到5.726亿美元，超过分析师预期的5.5933亿美元。这一营收增长可能是投资者看好公司未来发展的另一个重要因素。分析师和投资者似乎更关注公司的收入增长潜力，而非短期盈利波动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.